FMR1NB and lung carcinoma: These findings indicated that NY-SAR-35 is an attractive target for antigen-specific immunotherapy in lung cancer and that treatment with demethylating agents, in combination with immunotherapy, could be a useful therapeutic strategy for modulating the antigen expression.